Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP3K7 | O43318 | 1/20 | 0.69 |
| ▸ | EGFR | P00533 | 5/20 | 0.60 |
| ▸ | JAK3 | P52333 | 4/20 | 0.60 |
| ▸ | BTK | Q06187 | 4/20 | 0.60 |
| ▸ | JAK2 | O60674 | 4/20 | 0.60 |
| ▸ | JAK1 | P23458 | 3/20 | 0.60 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.60 |
| ▸ | PTK2 | Q05397 | 5/20 | 0.58 |
| ▸ | TTK | P33981 | 5/20 | 0.50 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.48 |
| ▸ | BRD4 | O60885 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18018872 | 0.86 | MAP3K7 (0.81) | MAP3K7EGFRJAK3BTKJAK2 | |
| SCHEMBL18018873 | 0.86 | MAP3K7 (0.68) | MAP3K7EGFRJAK3BTKJAK2 | |
| SCHEMBL23010735 | 0.83 | MAP3K7 (0.66) | MAP3K7EGFRJAK3BTKJAK2 | |
| SCHEMBL18018877 | 0.82 | MAP3K7 (0.81) | MAP3K7EGFRJAK3BTKJAK2 | |
| SCHEMBL18018787 | 0.82 | MAP3K7 (0.77) | MAP3K7EGFRJAK3BTKJAK2 | |
| SCHEMBL18018785 | 0.81 | MAP3K7 (1.00) | MAP3K7EGFRJAK3BTKJAK2 | |
| SCHEMBL18018878 | 0.76 | EGFR (0.79) | MAP3K7EGFRJAK3BTKJAK2 | |
| SCHEMBL15453409 | 0.75 | EGFR (1.00) | MAP3K7EGFRJAK3BTKJAK2 | |
| SCHEMBL15453488 | 0.74 | EGFR (0.70) | MAP3K7EGFRJAK3BTKJAK2 | |
| SCHEMBL15453489 | 0.74 | EGFR (0.72) | MAP3K7EGFRJAK3BTKJAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3778604-A1 | LRRK2 INHIBITORS AND METHODS OF MAKING AND USING THE SAME | Dana Farber Cancer Institute, Inc. (US) | 2021-02-17 | — | — | EP | disclosed |
| EP-3778605-A2 | LRRK2 INHIBITORS AND METHODS OF MAKING AND USING THE SAME | Dana Farber Cancer Institute, Inc. (US) | 2021-02-17 | — | — | EP | disclosed |